Last reviewed · How we verify

NCT04284124

Erector Spinae Block Versus PECS Block Type II for Breast Surgeries

Completed NA Last updated 2 November 2021
What this trial tests

NA trial testing Erector Spinae block in Analgesia in 60 participants. Completed in 10 March 2021.

Timeline
19 March 2020
Primary endpoint
10 March 2021
10 March 2021

Quick facts

Lead sponsorNational Cancer Institute, Egypt
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment60
Start date19 March 2020
Primary completion10 March 2021
Estimated completion10 March 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

National Cancer Institute, Egypt

Who can join

18 and older, female only, with Analgesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this randomized, controlled prospective study is to compare the analgesic effect of US-guided ESP block versus PECs block in patients undergoing breast surgery for breast cancer in the National Cancer Institute, Cairo University. We aim to evaluate the postoperative pain intensity and opioid consumption within 24 hours

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Erector Spinae Plane Block Versus PECS Block Type II for Breast Surgery: A Randomized Controlled Trial.
    Bakeer A, Abdallah NM. · · 2022 · cited 11× · PMID 35991781 · DOI 10.5812/aapm-122917

Verify or expand the search:

Other trials of Erector Spinae block

Trials testing the same drug.

Other recruiting trials for Analgesia

Currently open trials in the same condition.

Other National Cancer Institute, Egypt trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04284124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing